Literature DB >> 8849258

Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

H K Medlin1, Y Q Zhu, K M Remington, T R Phillips, T W North.   

Abstract

We have selected and plaque purified a mutant of feline immunodeficiency virus (FIV) that is resistant to 2',3'-dideoxycytidine (ddC). This mutant was selected in cultured cells in the continuous presence of 25 microM ddC. The mutant, designated DCR-5c, was fourfold resistant to ddC, threefold resistant to 2',3'-dideoxyinosine, and more than fourfold resistant to phosphonoformic acid. DCR-5c displayed little or no resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine, 3'-azido-3'-deoxythymidine, or 9-(2-phosphonylmethoxyethyl) adenine. Reverse transcriptase purified from DCR-5c was less susceptible to inhibition by ddCTP, phosphonoformic acid, ddATP, or azido-dTTP than the wild-type FIV reverse transcriptase. Sequence analysis of DCR-5c revealed a single base change (G to C at nucleotide 2342) in the reverse transcriptase-encoding region of FIV. This mutation results in substitution of His for Asp at codon 3 of FIV reverse transcriptase. The role of this mutation in ddC resistance was confirmed by site-directed mutagenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849258      PMCID: PMC163237     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses.

Authors:  R A Olmsted; V M Hirsch; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

3.  Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.

Authors:  B A Larder; S D Kemp; D J Purifoy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

5.  Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome.

Authors:  T W North; G L North; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

6.  Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

Authors:  H Jacobsen; K Yasargil; D L Winslow; J C Craig; A Kröhn; I B Duncan; J Mous
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

7.  Nucleotide sequence and genomic organization of feline immunodeficiency virus.

Authors:  R L Talbott; E E Sparger; K M Lovelace; W M Fitch; N C Pedersen; P A Luciw; J H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.

Authors:  J K Yamamoto; E Sparger; E W Ho; P R Andersen; T P O'Connor; C P Mandell; L Lowenstine; R Munn; N C Pedersen
Journal:  Am J Vet Res       Date:  1988-08       Impact factor: 1.156

9.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

10.  The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.

Authors:  Z Gu; R S Fletcher; E J Arts; M A Wainberg; M A Parniak
Journal:  J Biol Chem       Date:  1994-11-11       Impact factor: 5.157

View more
  5 in total

1.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Authors:  R A Smith; K M Remington; R M Lloyd; R F Schinazi; T W North
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Authors:  Y Q Zhu; K M Remington; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.

Authors:  R A Smith; K M Remington; B D Preston; R F Schinazi; T W North
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Phylogenetic and genetic analysis of feline immunodeficiency virus gag, pol, and env genes from domestic cats undergoing nucleoside reverse transcriptase inhibitor treatment or treatment-naïve cats in Rio de Janeiro, Brazil.

Authors:  Angelica N Martins; Sheila O Medeiros; Jose P Simonetti; Hermann G Schatzmayr; Amílcar Tanuri; Rodrigo M Brindeiro
Journal:  J Virol       Date:  2008-06-11       Impact factor: 5.103

Review 5.  Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.

Authors:  Katrin Hartmann; Anita Wooding; Michèle Bergmann
Journal:  Vet Sci       Date:  2015-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.